Geode Capital Management LLC Purchases 23,058 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Geode Capital Management LLC raised its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 68.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,597 shares of the company’s stock after purchasing an additional 23,058 shares during the period. Geode Capital Management LLC’s holdings in Centessa Pharmaceuticals were worth $905,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC grew its stake in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after buying an additional 1,509 shares during the last quarter. Quarry LP grew its stake in Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the last quarter. Sandia Investment Management LP purchased a new position in Centessa Pharmaceuticals during the 2nd quarter worth $90,000. Finally, Fred Alger Management LLC purchased a new position in Centessa Pharmaceuticals during the 2nd quarter worth $99,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $15.64 on Friday. The stock has a market capitalization of $2.06 billion, a PE ratio of -10.22 and a beta of 1.53. Centessa Pharmaceuticals plc has a 52-week low of $6.65 and a 52-week high of $18.97. The stock’s 50-day moving average price is $16.97 and its 200 day moving average price is $14.37. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $15.38, for a total transaction of $180,591.96. Following the transaction, the insider now owns 183,266 shares in the company, valued at approximately $2,818,631.08. The trade was a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 22,205 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $15.80, for a total value of $350,839.00. Following the transaction, the chief executive officer now owns 663,456 shares in the company, valued at $10,482,604.80. The trade was a 3.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 368,023 shares of company stock worth $6,335,574 in the last quarter. Company insiders own 11.59% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on CNTA shares. Guggenheim boosted their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday. They set a “buy” rating on the stock. BMO Capital Markets boosted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Finally, B. Riley began coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.